Partial clinical hold lifted in US for Phase 1 trial of ProJenX’s prosetin
The U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold that limited the use of certain dose…
Articles by Patricia Inácio, PhD
Ferrer to co-develop, market PIKfyve inhibitor VRG50635
Spanish pharmaceutical company Ferrer will co-develop and market Verge Genomics’ investigational PIKfyve inhibitor VRG50635 for the treatment of amyotrophic…
ALS Association supports work to bring rural patients into clinical trials
The ALS Association awarded $400,000 to University of Missouri-Columbia School of Medicine and its NextGen Precision Health Initiative as…
Promising findings seen in healthy volunteer study of Axoltis’ NX210c
Axoltis Pharma‘s new treatment candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases was deemed safe and…
VectorY raises millions to support antibody gene therapy for ALS
VectorY Therapeutics has raised about $138 million in funding aiming to bring into clinical testing VTx-002, its lead…
NeuroSense’s CMC earn FDA OK ahead of PrimeC Phase 3 trial
The U.S. Food and Drug Administration (FDA) has signed off on the chemistry, manufacturing, and controls (CMC) clinical development plan…
Lead PAS-003 candidate chosen to target key protein in ALS
Pasithea Therapeutics has selected a lead candidate for its PAS-003 program, which is intended to target a “velcro-like” protein…
Relyvrio extends survival by 10.4 months versus external ALS group
Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) in the CENTAUR trial significantly extended the median survival — by 10.4…
New EAP will make CNM-Au8 available outside of trials
The National Institutes of Health (NIH) has awarded about $45.1 million toward an expanded access program (EAP) of CNM-Au8,…
CHMP confirms its initial position against approving AMX0035 in EU
An advisory committee of the European Medicines Agency has maintained its recommendation not to approve AMX0035 for amyotrophic…